Note: Claims are shown in the official language in which they were submitted.
-16-
The embodiments of the invention in which an exclusive
property or privilege is claimed are defined as follows:
1. Use of one or more serotonin-mediated
neurotransmission enhancing drugs for the
manufacture of a medicament. for treating
disturbances of mood, disturbances of appetite,
or both, associated with premenstrual syndrome
in women.
2. Use according to Claim 1 wherein the one or
more drugs is selected from the group consisting
of drugs which enhance serotonin-mediated
neurotrans-mission by increasing the quantity
of serotonin present within brain synapses;
drugs which enhance serotonin-mediated
neuro-transmission by activating brain post-synaptic
serotonin receptors; and drugs which enhance
serotonin-mediated neurotransmission by
increasing the quantity of serotonin present
within brain synapses and by activating brain
post-synaptic serotonin receptors.
3. Use according to Claim 1 wherein the one or
more drugs is selected from the group
consisting of drugs which increase serotonin
production; drugs which cause serotonin
release; drugs which suppress serotonin
reuptake; drugs which block presynaptic
serotonin receptors; and drugs which block
monoamine oxidase.
-17-
4. Use according to Claim 1 wherein the one or
more drugs is selected from the group
consisting of tryptophan, lithium,
d-fenfluramine, d,l-fenfluramine,
chlorimi-pramine, cyanimipramine, fluoxetine, paroxetine,
fluvoxamine, citalopram, femoxetine,
cianopramine, ORG 6582, RU 25591, LM5008,
1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-
tetrahydro-1-naphthylamine, DU 24565,
indalpine, CGP 6085/A, WY 25093, alaprociate,
zimelidine, trazodone, amitriptyline,
imipramine, trimipramine, doxepin, protriptyline,
nortriptyline, dibenzoxazepine, metergoline,
methysergide, cyproheptadine, deprenyl,
isocarboazide, phenelzine, tranylcypromine,
furazolidone, procarbazine, moclobemide,
brofaromine quipazine, m-CCP, MK212 and
CM57493.
5. Use of
a. a drug which increases serotonin levels
within brain synapses and a drug which causes
serotonin release;
b. a drug which increases serotonin levels
within brain synapses and a drug which blocks
serotonin reuptake;
c. a drug which increases serotonin levels
within brain synapses and a drug which blocks
synaptic inhibition of serotonin release;
-18-
d. a drug which blocks serotonin reuptake and
a drug which blocks presynaptic inhibition of
serotonin release;
e. a drug which causes serotonin release and
a drug which blocks serotonin reuptake; or
f. a drug which causes serotonin release and
a drug which blocks presynaptic inhibition of
serotonin release; all for the manufacture of a
medicament for treating disturbances of mood,
disturbances of appetite, or both, associated
with premenstrual syndrome, in a woman having
premenstrual syndrome.
6. Use of
a. a drug selected from the group consisting
of a monoamine oxidase inhibitor, lithium and
tryptophan and a drug selected from the group
consisting of d-fenfluramine, d,l-fenfluramine,
chlorimipramine, cyanimipramine, fluoxetine,
paroxetine, fluvoxamine, citalopram,
femoxetine, cianopramine, ORG 6582, RU 25591
and LM5008, 1S-4S-N-methyl.-4-(3,4-
dichlorophenyl)-1,2,3,4-tetrahydro-1-
naphthylamine, DU 24565, indalpine, CGP 6085/A,
WY 25093, alaprociate, zimelidine, trazodone,
amitriptyline imipramine, trimipramine,
doxepin, protiptyline, nortiptyline and
dibenzoxazepine;
b. tryptophan and a drug selected from the
group consisting of: metergoline,
-19-
methysergide, cyproheptadine, deprenyl,
isocarboazide, phenelzine, tranylcypromine,
furazolidone, procarbazine, moclobemide and
brofaromine;
c. a drug selected from the group consisting
of fluoxetine, paroxetine, cyanimipramine,
fluvoxamine, citalopram, femoxetine, ciano-pramine,
ORG 6582, RU 25591, LM 5008, 1S-4S-N-
methyl-4-(3,4-dichlorophenyl)-1,2,3,4-
tetrahydro-1-naphthylamine, DU 24565,
indapline, CGP 6085/A, WY 25093, alaprociate,
zimelidine, trazodone, amitriptyline,
imipramine, trimipramine, doxepin, protriptyline,
nortriptyline, dibenzoxazepine, and a drug
selected from the group consisting of
metergoline, methysergide, and cyproheptadine; or
d. d-fenfluramine, d,l-fenfluramine or
chlorimipramine and a drug selected from the
group consisting of fluoxetine, fluvoxamine,
citalopram, femoxetine, paroxetine,
cianopramine, ORG 6582, RU 25591, LM5008,
1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-
tetrahydro-1-naphthylamine, DU 24565,
indalpine, CGP 6085/A, WY 25093, alaprociate,
zimelidine, trazodone cyanimipramine,
amitriptyline, imipramine, trimipramine, doxepin,
protriptyline, and dibenzoxazepine; all for the
manufacture of a medicament for treating
disturbances of mood, disturbances of appetite,
-20-
or both, associated with premenstrual syndrome,
in a woman having premenstrual syndrome.
7. Use of at least two serotoninergic drugs for
the manufacture of a medicament for treating
disturbances of mood, disturbances of appetite,
or both, associated with premenstrual syndrome,
in women.
8. Use according to Claim 7 wherein the serotoninergic
drugs are selected from the group
consisting of tryptophan, lithium, d-fenfluramine
d,l-fenfluramine, chlorimipramine,
cyanimipramine, fluoxetine, paroxetine, fluvoxamine,
citalopram, femoxetine, cianopramine, ORG 6582,
RU 25591, LM5008, 1S-4S-N-methyl-4-(3,4-
dichlorophenyl)-1,2,3,4-tetrahydro-1-
naphthylamine, DU 24565, indalpine, CGP 6085/A,
WY 25093, alaprociate, zimelidine, trazodone,
amitriptyline, imipramine, trimipramine,
doxepin, protriptyline, nor triptyline,
dibenzoxazepine, metergoline, methysergide,
cyproheptadine, quipazine, M-CCP, MK212,
CM57493, deprenyl, isocarboazide, phenelzine,
tranylcypromine, furazolidone, procarbazine,
moclobemide and brofaromine.
9. A composition for administration to women for
treating disturbances of mood, disturbances of
appetite, or bath, associated with premenstrual
-21-
syndrome, comprising at least two drugs which
enhance serotonin-mediated neurotransmission.
10. A composition of Claim 9 wherein the drugs are
selected from the group consisting of drugs
which enhance serotonin-mediated neurotransmisson
by increasing the quantity of serotonin
present within brain synapses; drugs which
enhance serotonin-mediated neurotransmission by
activating brain post-synaptic serotonin
receptors; and drugs which enhance
serotonin-mediated neurotransmission by increasing the
quantity of serotonin present within brain
synapses and by activating brain post-synaptic
serotonin receptors.
11. A composition of Claim 9 wherein the drugs are
selected from the group consisting of drugs
which increase serotonin production; drugs
which cause serotonin release; drugs which
suppress serotonin reuptake; drugs which block
presynaptic serotonin receptors; and drugs
which block monoamine oxidase.
2. A composition of Claim 9 wherein the drugs are
selected from the group consisting of
tryptophan, lithium, d-fenfluramine,
d,l-fenfluramine, chlorimipramine, cyanimipramine,
fluoxetine, paroxetine, fluvoxamine, citalopram,
femoxetine, cianopramine, ORG 6582, RU
-22-
25591, LM5008, 1S-4S-N-methyl-4-(3,4-dichloro-
phenyl)-1,2,3,4-tetrahydro-1-naphthylamine, DU
24565, indalpine, CGP 6085,/A, WY 25093,
alaprociate, zimelidine, trazodone, amitriptyline,
imipramine, trimipramine, doxepin, protriptyline,
nortriptyline, dibenzoxazepine, meter-goline,
methysergide, cyproheptadine, deprenyl,
isocarboazide, phenelzine, tranylcypromine,
furazolidone, procarbazine, moclobemide,
brofaromine quipazine, m-CCP, MK212 and
CM57493.
13. A composition for treating disturbances of
mood, disturbances of appetite, or both,
associated with premenstrual syndrome, in a
woman having premenstrual syndrome, comprising:
a. a drug which increases serotonin levels
within brain synapses and a drug which causes
serotonin release;
b. a drug which increases serotonin levels
within brain synapses and a drug which blocks
serotonin reuptake;
c. a drug which increases serotonin levels
within brain synapses and a drug which blocks
synaptic inhibition of serotonin release;
d. a drug which blocks serotonin reuptake and
a drug which blocks presynaptic inhibition of
serotonin release;
e. a drug which causes serotonin release and
a drug which blocks serotonin reuptake; or
-23-
f. a drug which causes serotonin release and
a drug which blocks presynaptic inhibition of
serotonin release.
14. A composition for treating disturbances of
mood, disturbances of appetite, or both,
associated with premenstrual syndrome, in a
woman having premenstrual :syndrome, comprising:
a. a drug selected from the group consisting
of a monoamine oxidase inhibitor, lithium and
tryptophan and a drug selected from the group
consisting of d-fenfluramine, d,l-fenfluramine,
chlorimipramine, cyanimipramine, fluoxetine,
paroxetine, fluvoxamine, citalopram,
femoxetine, cianopramine, ORG 6582, RU 25591
and LM5008, 1S-4S-N-methyl-4-(3,4-
dichlorophenyl)-1,2,3,4-tetrahydro-1-
naphthylamine, DU 24565, indalpine, CGP 6085/A,
WY 25093, alaprociate, zimelidine, trazodone,
amitriptyline imipramine, trimipramine,
doxepin, protiptyline, nortiptyline and
dibenzoxazepine;
b. tryptophan and a drug selected from the
group consisting of: metergoline,
methysergide, cyproheptadine, deprenyl, isocarboazide,
azide, phenelzine, tranylcypromine, furazolidone,
procarbazine, moclobemide and
brofaromine;
c. a drug selected from the group consisting
of fluoxetine, paroxetine, cyanimipramine,
-24-
fluvoxamine, citalopram, femoxetine,
cianopramine, ORG 6582, RU 25591, LM 5008,
1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-
tetrahydro-1-naphthylamine, DU 24565,
indapline, CGP 6085/A, WY 25093, alaprociate,
zimelidine, trazodone, amitriptyline,
imipramine, trimipramine, doxepin, protriptyline,
nortriptyline, dibenzoxazepine, and a drug
selected from the group consisting of
metergoline, methysergide, and cyproheptadine; or
d, d-fenfluramine, d,l-fenfluramine or
chlorimipramine and a drug selected from the
group consisting of fluoxetine, fluvoxamine,
citalopram, femoxetine, paroxetine,
cianopramine, ORG 6582, RU 25591, LM5008,
1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-
tetrahydro-1-naphthylamine, DU 24565,
indalpine, CGP 6085/A, WY 25093, alaprociate,
zimelidine, trazodone cyanimipramine,
amitriptyline, imipramine, trimipramine, doxepin,
protriptyline, and dibenzoxazepine.
15. A composition for administration to women for
treating disturbances of mood, disturbances of
appetite, or both, associated with premenstrual
syndrome, comprising at least two
serotoninergic drugs.
16. A composition of Claim 15 wherein the
serotoninergic drugs are selected from the
group
-25-
consisting of tryptophan, lithium, d-fenfluramine
d,l-fenfluramine, chlorimipramine, cyanimipramine,
fluoxetine, paroxetine, fluvoxamine, citalopram,
femoxetine, cianopramine, ORG 6582, RU 25591, LM5008,
1S-4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-
tetrahydro-1-naphthylamine, DU 24565, indalpine, CGP
6085/A, WY 25093, alaprociate, zimelidine, trazodone,
amitriptyline, imipramine, trimipramine, doxepin,
protriptyline, nor triptyline, dibenzoxazepine,
metergoline, methysergide, cyproheptadine, quipazine,
M-CCP, MK212, CM57493, deprenyl, isocarboazide,
phenelzine, tranylcypromine, furazolidone,
procarbazine, moclobemide and brofaromine.
17. Use of a drug which selectively enhances
serotoninmediated neurotransmission for treating
disturbances of mood, disturbances of appetite, or
both, associated with premenstrual syndrome.